Pseudopheochromocytoma induced by anxiolytic withdrawal

作者: Alida Páll , Gergely Becs , Annamária Erdei , Lívia Sira , Árpád Czifra

DOI: 10.1186/S40001-014-0053-9

关键词: Secondary hypertensionAnesthesiaEpilepsyPanic disorderNauseaAnxiolyticParoxysmal hypertensionEncephalopathyAlprazolamMedicine

摘要: Symptomatic paroxysmal hypertension without significantly elevated catecholamine concentrations and with no evidence of an underlying adrenal tumor is known as pseudopheochromocytoma. We describe the case a female patient hypertensive crises accompanied by headache, vertigo, tachycardia, nausea altered mental status. Previously, she was treated for longer period alprazolam due to panic disorder. Causes secondary were excluded. Neurological triggers (intracranial tumor, cerebral vascular lesions, hemorrhage, epilepsy) could not be detected. Setting diagnosis pseudopheochromocytoma treatment initiated alpha- beta-blockers resulting in reduced frequency symptoms. Alprazolam restarted at daily dose 1 mg. The patient’s clinical condition improved rapidly dosage decreased. conclude that withdrawal anxiolytic therapeutic regimen may generate sympathetic overdrive life-threatening malignant encephalopathy. emphasize can diagnosed only after exclusion causes hypertension. highlight importance psychopharmacological approach this entity.

参考文章(21)
Franco J. Vaccarino, Susan Rotzinger, Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. Journal of Psychiatry & Neuroscience. ,vol. 28, pp. 171- 181 ,(2003)
Jennifer Hunt, Julie Lin, Paroxysmal hypertension in a 48-year-old woman Kidney International. ,vol. 74, pp. 532- 535 ,(2008) , 10.1038/KI.2008.6
Oliver G. Cameron, Myung A. Lee, George C. Curtis, Daisy S. McCann, Endocrine and physiological changes during “spontaneous” panic attacks Psychoneuroendocrinology. ,vol. 12, pp. 321- 331 ,(1987) , 10.1016/0306-4530(87)90061-8
Jacques W. M. Lenders, Karel Pacak, McClellan M. Walther, W. Marston Linehan, Massimo Mannelli, Peter Friberg, Harry R. Keiser, David S. Goldstein, Graeme Eisenhofer, Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. ,vol. 287, pp. 1427- 1434 ,(2002) , 10.1001/JAMA.287.11.1427
Samuel J. Mann, Severe paroxysmal hypertension (pseudopheochromocytoma). Current Hypertension Reports. ,vol. 10, pp. 12- 18 ,(2008) , 10.1007/S11906-008-0005-2
Mallory E. Bowers, Dennis C. Choi, Kerry J. Ressler, Neuropeptide Regulation of Fear and Anxiety: Implications of Cholecystokinin, Endogenous Opioids, and Neuropeptide Y Physiology & Behavior. ,vol. 107, pp. 699- 710 ,(2012) , 10.1016/J.PHYSBEH.2012.03.004
T. Zornitzki, H. Knobler, A. Schattner, Reboxetine treatment and pseudopheochromocytoma QJM: An International Journal of Medicine. ,vol. 100, pp. 61- 62 ,(2006) , 10.1093/QJMED/HCL134
SM Seck, EF Ka, A Niang, B Diouf, Pseudopheochromocytoma: An uncommon cause of malignant hypertension Indian Journal of Nephrology. ,vol. 19, pp. 122- 124 ,(2009) , 10.4103/0971-4065.57111
Karel Pacak, W. Marston Linehan, Graeme Eisenhofer, McClellan M. Walther, David S. Goldstein, Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Annals of Internal Medicine. ,vol. 134, pp. 315- 329 ,(2001) , 10.7326/0003-4819-134-4-200102200-00016